ELVN Exercise Disclosure
Collins Helen Louise · SEC Form 4 · Filed Aug 19, 2026
Exercise
Calculated transaction value
$0
Collins Helen Louise Chief Medical Officer
ELVN
Enliven Therapeutics
ELVN
Transaction date
Aug 17, 2026
Public filing date
Aug 19, 2026
Filing lag
Filed 2 days later
ELVN daily price context
Close on/before transaction
$59.53
Aug 17, 2026
Close before public filing
$60.07
Aug 18, 2026
Return since public filing
-16.36%
Through Sep 17, 2026
Source details
- Reported owner
- Not disclosed
- Source asset code
- Derivative
- Security
- Stock Option (right to buy) on Common Stock
- Quantity / price
- 5,000 shares @ $0
- SEC ownership
- Direct
- Transaction code
- M
- Form
- 4
- Filing identifier
- 0001701247-26-000012
Filing cohort
Transactions in this filing
Showing 4 of 4
Trades
4
Issuers
1
Estimated value
$305.33K
Buys / sales
0 / 2
| Issuer | Transaction | Traded | Value |
|---|---|---|---|
| Enliven Therapeutics, Inc. ELVN | Exercise | Aug 17, 2026 | $12.4K |
| Enliven Therapeutics, Inc. ELVN | Sale | Aug 17, 2026 | $227.65K |
| Enliven Therapeutics, Inc. ELVN | Sale | Aug 17, 2026 | $65.28K |
| Enliven Therapeutics, Inc. ELVN Current | Exercise | Aug 17, 2026 | $0 |